CR20220228A - Anticuerpos trem2 y usos de estos - Google Patents

Anticuerpos trem2 y usos de estos

Info

Publication number
CR20220228A
CR20220228A CR20220228A CR20220228A CR20220228A CR 20220228 A CR20220228 A CR 20220228A CR 20220228 A CR20220228 A CR 20220228A CR 20220228 A CR20220228 A CR 20220228A CR 20220228 A CR20220228 A CR 20220228A
Authority
CR
Costa Rica
Prior art keywords
trem2 antibodies
trem2
antibodies
diseases
relates
Prior art date
Application number
CR20220228A
Other languages
English (en)
Inventor
Forest Hoyt Andrews
Ross Edward Fellows
Yaming Wang
Ying Tang
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CR20220228A publication Critical patent/CR20220228A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a anticuerpos TREM2 y usos de estos para tratar enfermedades tales como enfermedades neurodegenerativas.
CR20220228A 2019-11-22 2020-11-16 Anticuerpos trem2 y usos de estos CR20220228A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962939097P 2019-11-22 2019-11-22
PCT/US2020/060663 WO2021101823A1 (en) 2019-11-22 2020-11-16 Trem2 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CR20220228A true CR20220228A (es) 2022-06-08

Family

ID=73790267

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220228A CR20220228A (es) 2019-11-22 2020-11-16 Anticuerpos trem2 y usos de estos

Country Status (17)

Country Link
US (1) US20220281975A1 (es)
EP (1) EP4061842A1 (es)
JP (1) JP7368624B2 (es)
KR (1) KR20220084152A (es)
CN (1) CN114667295B (es)
AU (1) AU2020387380A1 (es)
BR (1) BR112022007944A2 (es)
CA (1) CA3159055A1 (es)
CO (1) CO2022006708A2 (es)
CR (1) CR20220228A (es)
DO (1) DOP2022000104A (es)
EC (1) ECSP22041169A (es)
IL (1) IL293018A (es)
JO (1) JOP20220119A1 (es)
MX (1) MX2022006145A (es)
PE (1) PE20221337A1 (es)
WO (1) WO2021101823A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170240631A1 (en) 2014-08-08 2017-08-24 Alector Llc Anti-trem2 antibodies and methods of use thereof
JP2018537956A (ja) * 2015-10-06 2018-12-27 アレクトル エルエルシー 抗ｔｒｅｍ２抗体及びその使用方法
CN109641961A (zh) * 2016-07-22 2019-04-16 德国神经退行性疾病研究中心 Trem2切割调节剂及其用途
PT3601358T (pt) 2017-08-03 2023-08-30 Alector Llc Anticorpos anti-trem2 e métodos de uso dos mesmos
EP3681909A1 (en) * 2017-09-14 2020-07-22 Denali Therapeutics Inc. Anti-trem2 antibodies and methods of use thereof
AU2018383709A1 (en) * 2017-12-12 2020-07-16 Pionyr Immunotherapeutics, Inc. Anti-TREM2 antibodies and related methods

Also Published As

Publication number Publication date
AU2020387380A1 (en) 2022-05-26
PE20221337A1 (es) 2022-09-13
CN114667295B (zh) 2024-03-29
IL293018A (en) 2022-07-01
DOP2022000104A (es) 2022-07-31
ECSP22041169A (es) 2022-06-30
KR20220084152A (ko) 2022-06-21
JOP20220119A1 (ar) 2023-01-30
EP4061842A1 (en) 2022-09-28
BR112022007944A2 (pt) 2022-07-12
US20220281975A1 (en) 2022-09-08
CN114667295A (zh) 2022-06-24
CA3159055A1 (en) 2021-05-27
CO2022006708A2 (es) 2022-05-31
MX2022006145A (es) 2022-06-17
WO2021101823A1 (en) 2021-05-27
JP7368624B2 (ja) 2023-10-24
JP2023502460A (ja) 2023-01-24

Similar Documents

Publication Publication Date Title
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
PH12019502283A1 (en) Anti-lag3 antibodies
PH12021550337A1 (en) Anti-gdf15 antibodies, compositions and methods of use
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
NZ738008A (en) Tigit-binding agents and uses thereof
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
MX2021008592A (es) Composiciones de trem y usos de las mismas.
PH12016501366A1 (en) Novel anti-baff antibodies
MX2018003174A (es) Metodos para tratar enfermedades inflamatorias.
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
ZA201800804B (en) Novel anti-human gpvi antibodies and uses thereof
PH12021550102A1 (en) Cardiosafe antidiabetic therapy
EP4273165A3 (en) Interferon beta antibodies and uses thereof
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
MX2021004454A (es) Anticuerpos anti-sinucleina.
MX2021006865A (es) Anticuerpos anti-alfa-sinucleina y usos de estos.
CR20220228A (es) Anticuerpos trem2 y usos de estos
MX2017009698A (es) Composiciones de inmunoglobulina equina y usos para tratar enfermedades mediadas por filovirus.
MX2019004182A (es) Proceso para la fabricacion de 2,6-dimetil-5-hepten-1-al.
MX2018001592A (es) Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos.
PH12019502694A1 (en) Anti-trkb antibodies
MX2017006692A (es) Trastornos neurodegenerativos.
MX2020010092A (es) Variantes de anticuerpo c-terminales.
EP4218817A3 (en) Methods for treating metabolic diseases by inhibiting myostatin activation
PH12017501872A1 (en) Methods of treating diseases